Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody

Cancer Immunology Immunotherapy

Volumn 49, Issue 3, 2000, Pages 173-180

  Renner, Christoph ^a   Hartmann, Frank ^a   Jung, Wolfram ^a   Deisting, Christina ^a   Juwana, Marieta ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Hodgkin's lymphoma; Immunotherapy; Monoclonal antibodies

Indexed keywords

BISPECIFIC ANTIBODY; CD30 ANTIGEN; FC RECEPTOR; IDIOTYPIC ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, CD30; ANTIGENS, NEOPLASM; BLOOD CELL COUNT; HODGKIN DISEASE; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MICE; RECEPTORS, IGG; SALVAGE THERAPY; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 0033935905     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050617     Document Type: Article

References (34)

1. Boerman OC, Segers MF, Poels LG, Kenemans P, Thomas CM (1990) Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 36: 888
2. Buist MR, Kenemans P, Kamp GJ xan, Haisma HJ (1995) Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 40: 24
3. Carter P, Ridgway J, Zhu Z (1995) Toward the production of bispecific antibody fragments for clinical applications. J Hematother 4: 463
4. Clark JI, Alpaugh RK, Mehren M von, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM (1997) Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother 44: 265
5. Diehl V, Kalle C von, Fonatsch C, Tesch H, Juecker M, Schaadt M (1990) The cell of origin in Hodgkin's disease. Semin Oncol 17: 660
6. Dillman RO, Shawler DL, McCallister TJ, Halpern SE (1994) Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabelled murine monoclonal antibodies. Cancer Biother 9: 17
7. Engert A, Martin G, Amlot P, Wijdenes J, Diehl V, Thorpe P (1991) Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int J Cancer 49: 450
8. Fagerberg J, Ragnhamar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE (1996) Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 42: 81
9. Fanger MW, Graziano RF, Guyre PM (1994) Production and use of anti-FcR bispecific antibodies. Immunomethods 4: 72
10. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L (1991) Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48: 227
11. Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM (1990) Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol 144: 2891
12. Gause A, Pohl C, Tschiersch A, Da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77: 1983
13. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89: 2042
14. Holliger P, Prospero T, Winter G (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444
15. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M (1993) A CD16/ CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55: 830
16. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91: 1706
17. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825
18. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK (1997) Induction of antitumot immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 57: 728
19. Pohl C, Renner C, Schwonzen M, Sieber M, Lorenz P, Pfreundschuh M, Diehl V (1992) Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B-and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies. Int J Cancer 50: 958
20. Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V (1993) CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int J Cancer 54: 418
21. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145: 179
22. Renner C, Jung W, Sahin U, Lier R van, Pfreundschuh M (1995) The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 25: 2027
23. Renner C, Bauer S, Sahin U, Jung W, Lier R van, Jacobs G, Held G, Pfreundschuh M (1996) Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 87: 2930
24. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M (1996) T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88: 236
25. Renner C, Hartmann F, Pfreundschuh M (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 45: 184
26. Riethmueller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788
27. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 50: 6944
28. Schobert I, Renner C, Pfreundschuh M, Diehl V, Pohl C (1994) Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin's lymphoma. Leuk Lymphoma 13: 429
29. Segal DM, Qian JH, Mezzanzanica D, Garrido MA, Titus JA, Andrew SM, George AJ, Jost CR, Perez P, Wunderlich JR (1992) Targeting of anti-tumor responses with bispecific antibodies. Immunobiology 185: 390
30. Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 155: 3253
31. Staerz UD, Yewdell JW, Bevan MJ (1987) Hybrid antibody-mediated lysis of virus-infected cells. Eur J Immunol 17: 571
32. Tajima F, Kawatani T, Endo A, Kawasaki H (1996) Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 10: 478
33. Thompson RJ, Jackson AP, Langlois N (1986) Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects: incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin Chem 32: 476
34. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55: 4586